Drug Database · Clinicians

Levocarnitine

Brands (3) Lecarnita, Levocarnil, MetacartinShow all

US brand (reference label): Carnitor; not a Philippine-registered brand.

Carnitine Analog US FDA class
Amino acids and derivatives PH FDA category

Rx · Prescription drug3 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID cf801cc4-775e-433d-9d32-e5d9a98981d3, version date November 20, 2023 (Carnitor · Leadiant Biosciences, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.

Contraindications

CONTRAINDICATIONS None known.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION CARNITOR ® Injection is administered intravenously. Metabolic Disorders The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion. Often a loading dose is given in patients with severe metabolic crisis, followed by an equivalent dose over the following 24 hours. It should be administered q3h or q4h, and never less than q6h either by infusion or by intravenous injection.

All subsequent daily doses are recommended to be in the range of 50 mg/kg or as therapy may require. The highest dose administered has been 300 mg/kg. It is recommended that a plasma carnitine concentration be obtained prior to beginning this parenteral therapy. Weekly and monthly monitoring is recommended as well. This monitoring should include blood chemistries, vital signs, plasma carnitine concentrations (the plasma free carnitine concentration should be between 35 and 60 µmol/L) and overall clinical condition.

ESRD Patients on Hemodialysis The recommended starting dose is 10-20 mg/kg dry body weight as a slow 2-3 minute bolus injection into the venous return line after each dialysis session. Initiation of therapy may be prompted by trough (pre-dialysis) plasma levocarnitine concentrations that are below normal (40-50 µmol/L).

Dose adjustments should be guided by trough (pre-dialysis) levocarnitine concentrations, and downward dose adjustments (e.g. to 5 mg/kg after dialysis) may be made as early as the third or fourth week of therapy. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (clinical pharmacology)

Renal Disease (ESRD) patients on maintenance hemodialysis may have low plasma carnitine concentrations and an increased ratio of acylcarnitine/carnitine because of reduced intake of meat and dairy products, reduced renal synthesis and dialytic losses. Certain clinical conditions common in hemodialysis patients such as malaise, muscle weakness, cardiomyopathy and cardiac arrhythmias may be related to abnormal carnitine metabolism.

Pharmacokinetic and clinical studies with CARNITOR ® have shown that administration of levocarnitine to ESRD patients on hemodialysis results in increased plasma levocarnitine concentrations.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use See Dosage and Administration.

Dosage forms

Philippines

  • ) solution for injection: 200 mg/mL (1 g/5 mL, 200 mg/mL (1000 mg/5 mL
  • Oral solution: 1 g/10 mL

Registered products in the Philippines

3 products registered with the Food and Drug Administration (FDA) Philippines list Levocarnitine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products3
Philippine FDA-registered products for Levocarnitine
Package insert
LecarnitaLevocarnitine
200 mg/mL (1000 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 5's)
Rx
Help S.A.Greece
First Global Trading CorporationTrader: Perrery International Ltd.
DRP–12209
Jun 30, 2027
LevocarnilLevocarnitine
200 mg/mL (1 g/5 mL) Solution for Injection (IV)Clear glass ampoule x 5 mL (Box of 5's)
Rx
Farbe Firma Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-14808
Mar 6, 2029
MetacartinLevocarnitine
1 g /10 mL Oral SolutionIn 15 mL - capacity Type III amber glass colored vial x 10 mL (Box of 1's)
Rx
World Medicine Ilac Sanayi Ve Ticaret A.S.Turkey
Ambicare Pharmaceuticals Inc.
DRP-15158
Jul 2, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following CARNITOR ® administration, mostly in patients with end stage renal disease who are undergoing dialysis. Some reactions occurred within minutes after intravenous administration of CARNITOR ®.

If a severe hypersensitivity reaction occurs, discontinue CARNITOR ® treatment and initiate appropriate medical treatment. Consider the risks and benefits of re-administering CARNITOR ® to individual patients following a severe reaction. If the decision is made to re-administer the product, monitor patients for a reoccurrence of signs and symptoms of a severe hypersensitivity reaction.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Clinical Trials Experience Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. An incidence for these reactions is difficult to estimate due to the confounding effects of the underlying pathology. The table below lists the adverse events that have been reported in two double-blind, placebo-controlled trials in patients on chronic hemodialysis.

Events occurring at ≥5% are reported without regard to causality. Adverse Events with a Frequency ≥5% Regardless of Causality by Body System Placebo (n=63) Levocarnitine 10 mg (n=34) Levocarnitine 20 mg (n=62) Levocarnitine 40 mg (n=34) Levocarnitine 10, 20 & 40 mg (n=130) Body as Whole Abdominal pain 17 21 5 6 9 Accidental injury 10 12 8 12 10 Allergic reaction 5 6 2 Asthenia 8 9 8 12 9 Back pain 10 9 8 6 8 Chest pain 14 6 15 12 12 Fever 5 6 5 12 7 Flu syndrome 40 15 27 29 25 Headache 16 12 37 3 22 Infection 17 15 10 24 15 Injection site reaction 59 38 27 38 33 Pain 49 21 32 35 30 Cardiovascular Arrhythmia 5 3 3 2 Atrial fibrillation 2 6 2 Cardiovascular disorder 6 3 5 6 5 Electrocardiogram abnormal 3 6 2 Hemorrhage 6 9 2 3 4 Hypertension 14 18 21 21 20 Hypotension 19 15 19 3 14 Palpitations 3 8 5 Tachycardia 5 6 5 9 6 Vascular disorder 2 2 6 2 Digestive Anorexia 3 3 5 6 5 Constipation 6 3 3 3 3 Diarrhea 19 9 10 35 16 Dyspepsia 10 9 6 5 Gastrointestinal disorder 2 3 6 2 Melena 3 6 2 Nausea 10 9 5 12 8 Stomach atony 5 Vomiting 16 9 16 21 15 Endocrine System Parathyroid disorder 2 6 2 6 4 Hemic/Lymphatic Anemia 3 3 5 12 6 Metabolic/Nutritional Hypercalcemia 3 15 8 6 9 Hyperkalemia 6 6 6 6 6 Hypervolemia 17 3 3 12 5 Peripheral edema 3 6 5 3 5 Weight decrease 3 3 8 3 5 Weight increase 2 3 6 2 Musculo-Skeletal Leg cramps 13 8 4 Myalgia 6 Nervous Anxiety 5 2 1 Depression 3 6 5 6 5 Dizziness 11 18 10 15 13 Drug dependence 2 6 2 Hypertonia 5 3 1 Insomnia 6 3 6 4 Paresthesia 3 3 3 12 5 Vertigo 6 2 Respiratory Bronchitis 5 3 3 Cough increase 16 10 18 9 Dyspnea 19 3 11 3 7 Pharyngitis 33 24 27 15 23 Respiratory disorder 5 Rhinitis 10 6 11 6 9 Sinusitis 5 2 3 2 Skin And Appendages Pruritus 13 8 3 5 Rash 3 5 3 3 Special Senses Amblyopia 2 6 3 Eye disorder 3 6 3 3 Taste perversion 2 9 3 Urogenital Urinary tract infect 6 3 3 2 Kidney failure 5 6 6 6 6 Postmarketing Experience The following adverse reactions have been reported: Neurologic Reactions: Seizures have been reported to occur in patients, with or without pre-existing seizure activity, receiving either oral or intravenous levocarnitine.

In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported. Hypersensitivity reactions: Anaphylaxis, laryngeal edema and bronchospasm (see WARNINGS).

Adverse reaction frequency tables (US label) US FDA label
Adverse Events with a Frequency ≥5% Regardless of Causality by Body System
Placebo (n=63)Levocarnitine 10 mg (n=34)Levocarnitine 20 mg (n=62)Levocarnitine 40 mg (n=34)Levocarnitine 10, 20 & 40 mg (n=130)
Body as Whole
Abdominal pain1721569
Accidental injury101281210
Allergic reaction562
Asthenia898129
Back pain109868
Chest pain146151212
Fever565127
Flu syndrome4015272925
Headache161237322
Infection1715102415
Injection site reaction5938273833
Pain4921323530
Cardiovascular
Arrhythmia5332
Atrial fibrillation262
Cardiovascular disorder63565
Electrocardiogram abnormal362
Hemorrhage69234
Hypertension1418212120
Hypotension191519314
Palpitations385
Tachycardia56596
Vascular disorder2262
Digestive
Anorexia33565
Constipation63333
Diarrhea199103516
Dyspepsia10965
Gastrointestinal disorder2362
Melena362
Nausea1095128
Stomach atony5
Vomiting169162115
Endocrine System
Parathyroid disorder26264
Hemic/Lymphatic
Anemia335126
Metabolic/Nutritional
Hypercalcemia315869
Hyperkalemia66666
Hypervolemia1733125
Peripheral edema36535
Weight decrease33835
Weight increase2362
Musculo-Skeletal
Leg cramps1384
Myalgia6
Nervous
Anxiety521
Depression36565
Dizziness1118101513
Drug dependence262
Hypertonia531
Insomnia6364
Paresthesia333125
Vertigo62
Respiratory
Bronchitis533
Cough increase1610189
Dyspnea1931137
Pharyngitis3324271523
Respiratory disorder5
Rhinitis1061169
Sinusitis5232
Skin And Appendages
Pruritus13835
Rash3533
Special Senses
Amblyopia263
Eye disorder3633
Taste perversion293
Urogenital
Urinary tract infect6332
Kidney failure56666

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Reproductive studies have been performed in rats and rabbits at doses up to 3.8 times the human dose on the basis of surface area and have revealed no evidence of impaired fertility or harm to the fetus due to CARNITOR ®. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Levocarnitine supplementation in nursing mothers has not been specifically studied. Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine. In nursing mothers receiving levocarnitine, any risks to the child of excess carnitine intake need to be weighed against the benefits of levocarnitine supplementation to the mother. Consideration may be given to discontinuation of nursing or of levocarnitine treatment.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval.

Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.

Pharmacokinetics (US label) US FDA label

PHARMACOKINETICS In a relative bioavailability study in 15 healthy adult male volunteers, CARNITOR ® Tablets were found to be bio-equivalent to CARNITOR ® Oral Solution. Following 4 days of dosing with 6 tablets of CARNITOR ® 330 mg b.i.d. or 2 g of CARNITOR ® oral solution b.i.d., the maximum plasma concentration (C max) was about 80 µmol/L and the time to maximum plasma concentration (T max) occurred at 3.3 hours.

The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of CARNITOR ® were described by a two-compartment model. Following a single i.v. administration, approximately 76% of the levocarnitine dose was excreted in the urine during the 0-24h interval. Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half life was 0.585 hours and the mean apparent terminal elimination half life was 17.4 hours.

The absolute bioavailability of levocarnitine from the two oral formulations of CARNITOR ®, calculated after correction for circulating endogenous plasma concentrations of levocarnitine, was 15.1 ± 5.3% for CARNITOR ® Tablets and 15.9 ± 4.9% for CARNITOR ® Oral Solution. Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h.

Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human. 9 In a 9-week study, 12 ESRD patients undergoing hemodialysis for at least 6 months received CARNITOR ® 20 mg/kg three times per week after dialysis. Prior to initiation of CARNITOR ® therapy, mean plasma levocarnitine concentrations were approximately 20 µmol/L pre-dialysis and 6 µmol/L post-dialysis.

The table summarizes the pharmacokinetic data (mean ± SD µmol/L) after the first dose of CARNITOR ® and after 8 weeks of CARNITOR ® therapy. N=12 Baseline Single dose 8 weeks C max - 1139 ± 240 1190 ± 270 Trough (pre-dialysis, pre-dose) 21.3 ± 7.7 68.4 ± 26.1 190 ± 55 After one week of CARNITOR ® therapy (3 doses), all patients had trough concentrations between 54 and 180 µmol/L (normal 40-50 µmol/L) and concentrations remained relatively stable or increased over the course of the study.

In a similar study in ESRD patients also receiving 20 mg/kg CARNITOR ® 3 times per week after hemodialysis, 12- and 24-week mean pre-dialysis (trough) levocarnitine concentrations were 189 (N=25) and 243 (N=23) µmol/L, respectively. In a dose-ranging study in ESRD patients undergoing hemodialysis, patients received 10, 20, or 40 mg/kg CARNITOR ® 3 times per week following dialysis (N~30 for each dose group).

Mean ± SD trough levocarnitine concentrations (µmol/L) by dose after 12 and 24 weeks of therapy are summarized in the table. 12 weeks 24 weeks 10 mg/kg 116 ± 69 148 ± 50 20 mg/kg 210 ± 58 240 ± 60 40 mg/kg 371 ± 111 456 ± 162 While the efficacy of CARNITOR ® to increase carnitine concentrations in patients with ESRD undergoing dialysis has been demonstrated, the effects of supplemental carnitine on the signs and symptoms of carnitine deficiency and on clinical outcomes in this population have not been determined.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Carnitor · Leadiant Biosciences, Inc. [US FDA-approved label, version 19, November 20, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .